IO Biotech plans to meet with the FDA this fall to discuss the data from the phase 3 trial of Cylembio and determine next ...

Results from the Phase II COLLECTiVE202 trial (NCT05370885) demonstrated a statistically significant difference between VE202 ...

In this Q&A, Rohit Nambisan, CEO of Lokavant, and Jonathan Crowther, head of predictive analytics, Pfizer, explore how AI is ...

With new systemic treatments now available for psoriatic disease, questions remain on the comparable efficacy and safety of these therapies.

According to SDIC Securities, the global AI-driven drug market has more than doubled since 2021, hitting $1.76 billion in ...

Q2 2025 Earnings Call Transcript August 14, 2025 Cellectar Biosciences, Inc. beats earnings expectations. Reported EPS is $-3 ...

GTB-3650 TriKE® Phase 1 trial has successfully completed Cohort 1 and Cohort 2 dosing, treating a total of four patients; following Cohort 2's formal safety review, it has advanced into Cohort 3 and ...

HHS' decision "could stagnate research that has the potential to save millions of lives," writes Simon Williams.

Identifying specific biomarkers and clinical characteristics is crucial for predicting a patient's response to both existing and emerging treatments for chronic spontaneous urticaria, thereby moving ...

Incyte Corporation (($CC:INCY.CUR)) announced an update on their ongoing clinical study. Study Overview: Incyte Corporation is conducting a Phase ...

Dosed first patient in SURF302 for intermediate risk non-muscle invasive bladder cancer (IR NMIBC) - - Cash, cash equivalents, and marketable securities of $296.3 ...